Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen, a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research.

The series encompasses both proven and entirely new media spanning two particle platforms; core-shell and thermally modified fully porous along with new biocompatible titanium hardware.

The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars.

The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation, and glycan mapping.

As an added benefit, all bioZen media, particle sizes and phases are available in Phenomenex’s new biocompatible titanium hardware, which minimizes secondary reactions, carryover and other recovery issues to provide better overall reproducibility than stainless steel hardware. It also minimizes the amount of time typically spent on column priming and does not interfere with protein or peptide integrity.

The bioZen thermally modified fully porous media is produced with Phenomenex’s proprietary post-synthetic thermal treatment process, which improves particle mechanical strength and inertness, providing significantly better peak shape and fewer unwanted secondary interactions than traditional LC media.

The thermally modified media pairs well with high-efficiency bioZen Core-Shell Technology media which delivers increased resolution and sensitivity inshorter retention time windows.

Both particle platforms undergo stringent QC testing to ensure consistent high quality, while all individual bioZen columns have QC protocols for specific biologic applications to confirm product performance and reproducibility.